Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial
- PMID: 31897941
- DOI: 10.1007/s10072-019-04181-y
Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial
Abstract
Introduction: The objective of this trial was to evaluate the efficacy and safety of Cerebrolysin in treating patients after moderate to severe traumatic brain injury (TBI) as an adjunct to standard care protocols. The trial was designed to investigate the clinical effects of Cerebrolysin in the acute (neuroprotective) stage and during early and long-term recovery as part of a neurorestorative strategy.
Materials and methods: The study was a phase IIIb/IV single-center, prospective, randomized, double-blind, placebo-controlled clinical trial. Eligible patients with a Glasgow Coma Score (GCS) between 7 and 12 received study medication (50 ml of Cerebrolysin or physiological saline solution per day for 10 days, followed by two additional treatment cycles with 10 ml per day for 10 days) in addition to standard care. We tested ensembles of efficacy criteria for 90, 30, and 10 days after TBI with a priori ordered hypotheses using a multivariate, directional test, to reflect the global status of patients after TBI.
Results: The study enrolled 142 patients, of which 139 underwent formal analysis (mean age = 47.4, mean admission GCS = 10.4, and mean Baseline Prognostic Risk Score = 2.6). The primary endpoint, a multidimensional ensemble of 13 outcome scales, indicated a "small-to-medium"-sized effect in favor of Cerebrolysin, statistically significant at day 90 (MWcombined = 0.59, 95% CI 0.52 to 0.66, P = 0.0119). Safety and tolerability observations were comparable between treatment groups.
Conclusion: Our trial confirms previous beneficial effects of the multimodal, biological agent Cerebrolysin for overall outcome after moderate to severe TBI, as measured by a multidimensional approach. Study findings must be appraised and aggregated in conjunction with existing literature, as to improve the overall level of insight regarding therapeutic options for TBI patients. The widely used pharmacologic intervention may benefit from a large-scale observational study to map its use and to establish comparative effectiveness in real-world clinical settings.
Keywords: Cerebrolysin; Multidimensional approach; Traumatic brain injury; Wei-Lachin pooling.
Similar articles
-
Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series.Neurol Sci. 2021 Nov;42(11):4531-4541. doi: 10.1007/s10072-020-04974-6. Epub 2021 Feb 23. Neurol Sci. 2021. PMID: 33620612
-
Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial.Neurol Sci. 2020 Feb;41(2):281-293. doi: 10.1007/s10072-019-04053-5. Epub 2019 Sep 7. Neurol Sci. 2020. PMID: 31494820 Clinical Trial.
-
The Effect of Cerebrolysin on the Predictive Value of Baseline Prognostic Risk Score in Moderate and Severe Traumatic Brain Injury.J Med Life. 2020 Jul-Sep;13(3):283-288. doi: 10.25122/jml-2020-0146. J Med Life. 2020. PMID: 33072197 Free PMC article. Clinical Trial.
-
Another failed attempt of neuroprotection: progesterone for moderate and severe traumatic brain injury.Minerva Anestesiol. 2016 Apr;82(4):486-91. Epub 2015 Jul 1. Minerva Anestesiol. 2016. PMID: 26126980 Review.
-
A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury.Neurosurg Rev. 2018 Apr;41(2):427-438. doi: 10.1007/s10143-016-0775-y. Epub 2016 Aug 18. Neurosurg Rev. 2018. PMID: 27539610 Review.
Cited by
-
Prediction of Neurocognitive Outcome after Moderate-Severe Traumatic Brain Injury Using Serum Neuron-Specific Enolase and S100 biomarkers.J Med Life. 2020 Jul-Sep;13(3):306-313. doi: 10.25122/jml-2020-0147. J Med Life. 2020. PMID: 33072201 Free PMC article.
-
A novel pharmacological treatment concept for neuroprotection in severe traumatic brain injury-Two case reports.Clin Case Rep. 2022 Nov 20;10(11):e6626. doi: 10.1002/ccr3.6626. eCollection 2022 Nov. Clin Case Rep. 2022. PMID: 36419580 Free PMC article.
-
The Effect of Cerebrolysin on Anxiety, Depression, and Cognition in Moderate and Severe Traumatic Brain Injury Patients: A CAPTAIN II Retrospective Trial Analysis.Medicina (Kaunas). 2022 May 9;58(5):648. doi: 10.3390/medicina58050648. Medicina (Kaunas). 2022. PMID: 35630065 Free PMC article.
-
Cerebrolysin and repetitive transcranial magnetic stimulation (rTMS) in patients with traumatic brain injury: a three-arm randomized trial.Front Neurosci. 2023 Jun 8;17:1186751. doi: 10.3389/fnins.2023.1186751. eCollection 2023. Front Neurosci. 2023. PMID: 37360156 Free PMC article.
-
Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study.Healthcare (Basel). 2023 May 21;11(10):1497. doi: 10.3390/healthcare11101497. Healthcare (Basel). 2023. PMID: 37239783 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical